JP2011502966A - ドーパミントランスポーターレベルを評価することによるレビー小体型認知症の診断およびレビー小体型認知症の処置のモニタリングのための方法 - Google Patents
ドーパミントランスポーターレベルを評価することによるレビー小体型認知症の診断およびレビー小体型認知症の処置のモニタリングのための方法 Download PDFInfo
- Publication number
- JP2011502966A JP2011502966A JP2010531330A JP2010531330A JP2011502966A JP 2011502966 A JP2011502966 A JP 2011502966A JP 2010531330 A JP2010531330 A JP 2010531330A JP 2010531330 A JP2010531330 A JP 2010531330A JP 2011502966 A JP2011502966 A JP 2011502966A
- Authority
- JP
- Japan
- Prior art keywords
- dopamine transporter
- patient
- lewy body
- dementia
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 title claims abstract description 132
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 title claims abstract description 131
- 201000002832 Lewy body dementia Diseases 0.000 title claims abstract description 123
- 208000009829 Lewy Body Disease Diseases 0.000 title claims abstract description 61
- 238000000034 method Methods 0.000 title claims abstract description 45
- 238000003745 diagnosis Methods 0.000 title claims description 28
- 238000011282 treatment Methods 0.000 title description 29
- 238000012544 monitoring process Methods 0.000 title description 5
- 239000003446 ligand Substances 0.000 claims abstract description 40
- 230000027455 binding Effects 0.000 claims abstract description 36
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 12
- 238000002603 single-photon emission computed tomography Methods 0.000 claims abstract description 6
- GTQLIPQFXVKRKJ-HYRAKNMCSA-N methyl (1s,3s,4s,5r)-3-(4-fluorophenyl)-8-[(e)-3-iodanylprop-2-enyl]-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C\C=C\[123I])[C@H]2C(=O)OC)=CC=C(F)C=C1 GTQLIPQFXVKRKJ-HYRAKNMCSA-N 0.000 claims description 46
- 238000003384 imaging method Methods 0.000 claims description 42
- 210000001577 neostriatum Anatomy 0.000 claims description 31
- 210000004558 lewy body Anatomy 0.000 claims description 22
- 238000011156 evaluation Methods 0.000 claims description 21
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 19
- 210000004556 brain Anatomy 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 230000007423 decrease Effects 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 230000001629 suppression Effects 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 abstract description 22
- 238000002347 injection Methods 0.000 description 30
- 239000007924 injection Substances 0.000 description 30
- GTQLIPQFXVKRKJ-UNSMHXHVSA-N altropane Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C\C=C\I)[C@H]2C(=O)OC)=CC=C(F)C=C1 GTQLIPQFXVKRKJ-UNSMHXHVSA-N 0.000 description 24
- 229950004560 altropane Drugs 0.000 description 24
- 210000003128 head Anatomy 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 208000024827 Alzheimer disease Diseases 0.000 description 18
- 238000003759 clinical diagnosis Methods 0.000 description 17
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
- 238000002600 positron emission tomography Methods 0.000 description 12
- 201000004810 Vascular dementia Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 210000002637 putamen Anatomy 0.000 description 10
- 230000002159 abnormal effect Effects 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 210000000225 synapse Anatomy 0.000 description 7
- 230000000007 visual effect Effects 0.000 description 7
- 208000018737 Parkinson disease Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229960003638 dopamine Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 210000004227 basal ganglia Anatomy 0.000 description 5
- 210000001159 caudate nucleus Anatomy 0.000 description 5
- 230000001149 cognitive effect Effects 0.000 description 5
- 238000013102 re-test Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- QUSLQENMLDRCTO-YJNKXOJESA-N win 35428 Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@H]2C(=O)OC)=CC=C(F)C=C1 QUSLQENMLDRCTO-YJNKXOJESA-N 0.000 description 5
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 208000016285 Movement disease Diseases 0.000 description 4
- 208000027089 Parkinsonian disease Diseases 0.000 description 4
- 206010034010 Parkinsonism Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000000133 brain stem Anatomy 0.000 description 4
- 239000002872 contrast media Substances 0.000 description 4
- 230000001054 cortical effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- DGGKXQQCVPAUEA-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octane Chemical compound C1CCC2CCC1N2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002739 subcortical effect Effects 0.000 description 3
- 229910052713 technetium Inorganic materials 0.000 description 3
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 description 3
- OJSLUXYIIKQTPB-KGLIPLIRSA-N (1r,5s)-8-methyl-5-phenyl-8-azabicyclo[3.2.1]octane Chemical compound C1([C@@]23CC[C@@](CCC2)(N3C)[H])=CC=CC=C1 OJSLUXYIIKQTPB-KGLIPLIRSA-N 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 241001296096 Probles Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- HXWLAJVUJSVENX-HFIFKADTSA-N ioflupane I(123) Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3CCCF)[C@H]2C(=O)OC)=CC=C([123I])C=C1 HXWLAJVUJSVENX-HFIFKADTSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000478 neocortex Anatomy 0.000 description 2
- 238000010984 neurological examination Methods 0.000 description 2
- 230000007121 neuropathological change Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108091077621 MAPRE family Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 102000005029 SLC6A3 Human genes 0.000 description 1
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 201000007197 atypical autism Diseases 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 238000000876 binomial test Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000004886 head movement Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002496 iodine Chemical class 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940033872 namenda Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 230000007507 senile plaque formation Effects 0.000 description 1
- 208000022288 senile plaque formation Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 238000003569 transporter assay Methods 0.000 description 1
- 229930004006 tropane Natural products 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000006496 vascular abnormality Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K51/0448—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil tropane or nortropane groups, e.g. cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98419407P | 2007-10-31 | 2007-10-31 | |
| PCT/US2008/081569 WO2009058851A2 (en) | 2007-10-31 | 2008-10-29 | Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011502966A true JP2011502966A (ja) | 2011-01-27 |
| JP2011502966A5 JP2011502966A5 (enExample) | 2012-11-15 |
Family
ID=40591729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531330A Pending JP2011502966A (ja) | 2007-10-31 | 2008-10-29 | ドーパミントランスポーターレベルを評価することによるレビー小体型認知症の診断およびレビー小体型認知症の処置のモニタリングのための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20100312105A1 (enExample) |
| EP (1) | EP2211911A4 (enExample) |
| JP (1) | JP2011502966A (enExample) |
| CA (1) | CA2703563A1 (enExample) |
| WO (1) | WO2009058851A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009040727A2 (en) * | 2007-09-26 | 2009-04-02 | Philips Intellectual Property & Standards Gmbh | Method of differentially diagnosing different types of dementia |
| KR20160138339A (ko) * | 2013-03-15 | 2016-12-05 | 아담 제이 사이먼 | 뇌 건강의 다중-모드 약리-진단 평가 |
| WO2014143896A2 (en) | 2013-03-15 | 2014-09-18 | Simon Adam J | System and signatures for the multi-modal physiological stimulation and assessment of brain health |
| GB201313291D0 (en) * | 2013-07-25 | 2013-09-11 | Ge Healthcare Ltd | Imaging neurological disease |
| CN104720840A (zh) * | 2015-02-11 | 2015-06-24 | 清华大学深圳研究生院 | 基于多巴胺转运体显像特异性摄取比的半自动量化方法 |
| EP3579887A4 (en) * | 2017-02-10 | 2020-09-16 | Likeminds, Inc. | PROCEDURE FOR IN VIVO MONITORING OF DOPAMINER DISORDERS AND EFFECTIVENESS OF TREATMENT PRODUCTS THEREFORE |
| WO2020018743A1 (en) * | 2018-07-18 | 2020-01-23 | Likeminds, Inc. | Method for accelerated tissue penetration of compounds into brain |
| AU2019319837A1 (en) * | 2018-08-07 | 2021-02-25 | Likeminds, Inc. | Method for diagnosis of dopaminergic and movement disorders |
| TWI686178B (zh) * | 2019-10-09 | 2020-03-01 | 中原大學 | 自動化定位核子醫學腦部影像紋狀體與計算紋狀體專一性攝取率的方法與系統 |
| WO2021092096A1 (en) * | 2019-11-06 | 2021-05-14 | Likeminds, Inc. | Individualized dosing of radioactive tracers for imaging |
| WO2022240817A1 (en) * | 2021-05-13 | 2022-11-17 | Likeminds, Inc. | Methods of visualizing dopamine transporters |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010540512A (ja) * | 2007-09-26 | 2010-12-24 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 異なるタイプの認知症を特異的に診断する方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7081238B2 (en) * | 1995-11-03 | 2006-07-25 | The President And Fellows Of Harvard College | Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level |
| CA2304505A1 (en) * | 1997-09-24 | 1999-04-01 | Nova Molecular, Inc. | Methods for increasing apoe levels for the treatment of neurodegenerative disease |
| AU2001249091A1 (en) * | 2000-03-03 | 2001-09-17 | Eisai Co. Ltd. | Novel methods using cholinesterase inhibitors |
| UY27003A1 (es) * | 2000-11-06 | 2002-07-31 | Schering Ag | Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer |
| AU2003291358A1 (en) * | 2002-11-07 | 2004-06-03 | Molecular Geriatrics Corporation | Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease |
| US20080302950A1 (en) * | 2005-08-11 | 2008-12-11 | The Brigham And Women's Hospital, Inc. | System and Method for Performing Single Photon Emission Computed Tomography (Spect) with a Focal-Length Cone-Beam Collimation |
| CA2628108C (en) * | 2005-11-10 | 2020-01-07 | Certara Usa, Inc. | Method and apparatus for computer modeling the human brain for predicting drug effects |
| EP2604290A3 (en) * | 2006-05-02 | 2013-07-10 | The Trustees of The University of Pennsylvania | Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents |
| US8084018B2 (en) * | 2007-10-31 | 2011-12-27 | Alseres Pharmaceuticals, Inc. | Methods for imaging dopamine transporter level |
| US8557222B2 (en) * | 2008-04-04 | 2013-10-15 | Avid Radiopharmaceuticals, Inc. | Radiopharmaceutical imaging of neurodegenerative diseases |
| EP3521309A1 (en) * | 2008-12-19 | 2019-08-07 | Biogen International Neuroscience GmbH | Human anti-alpha-synuclein antibodies |
| CA2764387A1 (en) * | 2009-06-05 | 2010-12-09 | Link Medicine Corporation | Aminopyrrolidinone derivatives and uses thereof |
| GB0922304D0 (en) * | 2009-12-22 | 2010-02-03 | Ge Healthcare Ltd | Radioiodinated compounds |
-
2008
- 2008-10-29 US US12/739,220 patent/US20100312105A1/en not_active Abandoned
- 2008-10-29 EP EP08845020A patent/EP2211911A4/en not_active Withdrawn
- 2008-10-29 JP JP2010531330A patent/JP2011502966A/ja active Pending
- 2008-10-29 CA CA2703563A patent/CA2703563A1/en not_active Abandoned
- 2008-10-29 WO PCT/US2008/081569 patent/WO2009058851A2/en not_active Ceased
-
2016
- 2016-01-11 US US14/992,510 patent/US20160121003A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010540512A (ja) * | 2007-09-26 | 2010-12-24 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 異なるタイプの認知症を特異的に診断する方法 |
Non-Patent Citations (5)
| Title |
|---|
| ANTONINI,A., NEUROPSYCHIATRIC DISEASE AND TREATMENT, vol. 3, no. 3, JPN6013025706, June 2007 (2007-06-01), pages 287 - 92, ISSN: 0002541827 * |
| MADRAS,B.K. ET AL, SYNAPSE, vol. 29, no. 2, JPN6013025709, 1998, pages 93 - 104, ISSN: 0002541828 * |
| MCKEITH,I. ET AL, LANCET NEUROLOGY, vol. 6, no. 4, JPN6013025705, April 2007 (2007-04-01), pages 305 - 13, ISSN: 0002541826 * |
| O'BRIEN,J.T. ET AL, ARCHIVES OF NEUROLOGY, vol. 61, no. 6, JPN6013025703, 2004, pages 919 - 25, ISSN: 0002541825 * |
| WALKER,Z. ET AL, NEUROLOGY, vol. 62, no. 9, JPN6013025701, 2004, pages 1568 - 1572, ISSN: 0002541824 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009058851A3 (en) | 2010-01-14 |
| CA2703563A1 (en) | 2009-05-07 |
| WO2009058851A2 (en) | 2009-05-07 |
| EP2211911A4 (en) | 2012-11-14 |
| EP2211911A2 (en) | 2010-08-04 |
| US20160121003A1 (en) | 2016-05-05 |
| US20100312105A1 (en) | 2010-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011502966A (ja) | ドーパミントランスポーターレベルを評価することによるレビー小体型認知症の診断およびレビー小体型認知症の処置のモニタリングのための方法 | |
| JP5603855B2 (ja) | 神経変成疾患の放射性薬剤による画像化 | |
| JP2011502966A5 (enExample) | ||
| Ossenkoppele et al. | Longitudinal imaging of Alzheimer pathology using [11C] PIB,[18F] FDDNP and [18F] FDG PET | |
| EP3024501B1 (en) | Imaging neurological disease | |
| Wong et al. | First in-human PET study of 3 novel tau radiopharmaceuticals:[11C] RO6924963,[11C] RO6931643, and [18F] RO6958948 | |
| JP2014148529A (ja) | ドーパミン輸送体レベルを造影するための方法 | |
| Döbert et al. | Diagnostic value of FDG-PET and HMPAO-SPET in patients with mild dementia and mild cognitive impairment: metabolic index and perfusion index | |
| Villemagne et al. | Amyloid imaging | |
| Sedaghat et al. | Evaluation of dopaminergic function in frontotemporal dementia using 123I-FP-CIT single photon emission computed tomography | |
| US20210162078A1 (en) | Method for diagnosis of dopaminergic and movement disorders | |
| US7553478B2 (en) | Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level | |
| Suppiah et al. | diagnostics MDPI | |
| Kumar et al. | Prospective Assessment of Alzheimer's Disease-Like Hypometabolism Pattern in the Brain of Diabetics in Contrast to Non-diabetics on Positron Emission Tomography-Computed Tomography Images Using Fluorodeoxyglucose in India | |
| Aye | Dual-phase PET imaging in cognitive impairment: an imaging study of amyloid and tau PET as measures of neurodegeneration and protein pathology | |
| Palandira et al. | Non-invasive identification of brain signatures of acute liver injury | |
| Hatashita | Mini-dictionary of terms | |
| Chiotis | Molecular imaging of tau in the pathological cascade of Alzheimer’s disease | |
| Coakeley | PET Imaging of Pathological Tau in Progressive Supranuclear Palsy | |
| Nair et al. | Amyloid imaging | |
| Scheinin | EARLY DETECTION OF ALZHEIMER’S DISEASE β-AMYLOID PATHOLOGY | |
| Ponto | Positron Emission Tomography (PET) Imaging: Principles and Potential Role in Understanding Brain Function | |
| Betthauser | Investigation of Novel Positron Emission Tomography Radioligands for in Vivo Characterization of Alzheimer's Disease Pathophysiology | |
| Ossenkoppele et al. | Longitudinal Imaging of Alzheimer Pathology using [P | |
| Tepmongkol | PET Imaging in Alzheimer’s Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20111028 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111028 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120918 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20121004 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121004 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130528 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130827 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130903 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130927 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131004 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131025 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131101 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140425 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140702 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20140725 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150403 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150417 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160106 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160205 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160304 |